阿斯利康周三表示,其实验性药物Anselamimab没有达到治疗AL淀粉样变性疾病的晚期研究的主要目标。AL淀粉样变性是一种罕见的疾病,会导致体内蛋白质沉积增多,造成重大器官损伤。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.